/
RVTY
$111.64+$0.43 (+0.38%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$12.6B
112M shares
52-week range
$81.22 – $118.30
82% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NYSE
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-2.57
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.78B | $2.88B | $3.78B | $3.83B | $3.31B | $2.75B | $2.76B | $2.86B |
| Cost of revenue | $1.53B | $1.59B | $1.79B | $1.55B | $1.55B | $1.43B | $1.43B | $1.34B |
| Gross profit | $1.25B | $1.29B | $1.99B | $2.28B | $1.76B | $1.32B | $1.32B | $1.52B |
| Gross margin | 45.0% | 44.8% | 52.6% | 59.6% | 53.2% | 48.1% | 48.0% | 53.1% |
| R&D | $186.1M | $189.3M | $205.4M | $200.3M | $221.6M | $216.6M | $196.8M | $215.8M |
| Operating income | $371.0M | $405.5M | $1.02B | $1.34B | $781.1M | $399.5M | $410.5M | $356.6M |
| EBITDA | $505.2M | $514.8M | $1.20B | $1.62B | $1.18B | $713.6M | $840.3M | $662.7M |
| Net income | $238.8M | $227.6M | $728.1M | $943.2M | $569.2M | −$118.4M | $295.8M | $241.7M |
| Net margin | 8.6% | 7.9% | 19.2% | 24.6% | 17.2% | -4.3% | 10.7% | 8.5% |
| EPS (diluted) | 2.14 | 2.04 | 6.49 | 8.08 | 4.50 | -0.95 | 2.41 | 2.08 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.8B | $5.24 | $5.23–$5.25 | 6 |
| 2027 | $3.0B | $5.82 | $5.81–$5.84 | 6 |
| 2028 | $3.2B | $6.46 | $6.35–$6.57 | 2 |
| 2029 | $3.3B | $6.88 | $6.78–$7.02 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$103.93
Price
$111.64
Implied downside
-7%
Peer comparison
Revvity, Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
www.revvity.com- Employees
- 11,000
- IPO / List date
- Jun 1, 1972
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds RVTY.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 37,064 | $3.2M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 0.25% ($0.28/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-17 | $0.0700 | 2026-08-07 |
| 2026-04-17 | $0.0700 | 2026-05-08 |
| 2026-01-16 | $0.0700 | 2026-02-06 |
| 2025-10-17 | $0.0700 | 2025-11-07 |
| 2025-07-18 | $0.0700 | 2025-08-08 |
| 2025-04-17 | $0.0700 | 2025-05-09 |
| 2025-01-17 | $0.0700 | 2025-02-07 |
| 2024-10-18 | $0.0700 | 2024-11-08 |
| 2024-07-19 | $0.0700 | 2024-08-09 |
| 2024-04-18 | $0.0700 | 2024-05-10 |
Recent trades on TradeandTell
No one on the platform has traded RVTY yet.
